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Abstract
Background and Aims: HCV infection may lead to hepatic fibrosis. In this study, we tried to determine whether
there is any correlation of HCV genotypes and viral load to the clinical parameters such as ALT, AST, ALP, bilirubin,
Hb level, patient’s age and gender; and then correlated this association with disease progression in liver biopsy
samples.
Methods: In cross-sectional and observational study, 6048 serum HCV RNA positive patients were chosen. The
study consists of 53 months from March 2006 to September 2010. Patients were divided into three cohorts to
validate our data. Statistical analysis and correlation of lab parameters with viral factors was determined by using
SPSS version 16.
Results: The most prevalent genotype was 3 (70.9%) followed by 1 (13.3%) and 4 (7.4%), collectively. During
Univariate analysis, in all cohorts; serum bilirubin, ALP, ALT and AAR showed significant correlation with genotypes,
however multivariate analysis showed that all genotypes except 4a have no association with host biochemical
markers. Disease progression was also independent of all genotypes. Serum ALP, ALT, bilirubin and viremea levels
were significantly elevated in patients with genotype 4a. Viral load showed negative association with serum
bilirubin (r = -0.112, P = 0.000) and ALP levels (r = -0.098, P = 0.000). We observed positive correlation of ALP and
bilirubin levels, while negative associations of viral load with HCV liver disease progression.
Conclusion: Disease progression seems independent of the genotypes. Relationship between ALP and bilirubin
with viral load may be an attractive marker to guess disease progression in patients with hepatitis C.
Introduction
Approximately 3% of the world’s populations, (more
than 350 million people) and about, 10 million people
in Pakistan [1] are chronically infected with hepatitis C
virus (HCV). HCV is the main cause of liver fibrosis,
cirrhosis and hepatocellular carcinoma (HCC) in a sub-
stantial number of patients [2]. Due to considerable
sequence diversity HCV is classified into a series of gen-
otypes showed distinct geographical and frequency dis-
tribution across the whole world [3-5].
In patients infected with HCV, clinical findings, geno-
types and viral load are strong predictors for the out-
come of antiviral therapy [6,7]. The most prevalent
genotype in Pakistan is 3a followed by 3b and 1a [8].
Due to high prevalence of genotype 3a in Pakistan;
HCV genotyping is not recommended in HCV infected
patients routinely by Pakistan’s society of Gastroenterol-
ogy [9]. Secondly, due to poverty and cost of genotyping
test, many patients do not agree for this test. Neverthe-
less, genotyping is important because it not only pro-
vides information as to strain variation and potential
association with disease severity but is also related to
the possibility of treatment response [10]. It is reported
that treatment with interferon is more effective in
patients with genotypes 2 and 3 than in patients infected
with genotypes 1 and 4 [11]. An assessment of the dis-
ease development based on clinical findings is still criti-
cal for patients infected with HCV. Several authors tried
to correlate viral and host biochemical factors like geno-
type, viral load, ALT, AST, bilirubin etc with each other
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as well as with liver damage, but no clear conclusions
were formed [12-16].
In the present study, we investigated the correlation of
several clinical findings like Hb, bilirubin, ALT, ALP
and AST levels, and AAR with viral factors (viral load
and genotypes) in patients infected with HCV; and their
outcome with fibrosis stages. We collected the HCV
positive samples and observed the best relation of serum
markers and viral factors and assess this relation in liver
histological grading for disease progression.
Patients and methods
Patients
Patients of this study were the people referred to Pathology
department, Jinnah Hospital and Mayo Hospital Lahore;
and Liver Centre Faisalabad Pakistan, for biochemical and
serological tests. This analytical study was carried out from
March 2006 to September 2010 in collaboration of
National Centre of Excellence in Molecular Biology, Uni-
versity of the Punjab, Lahore, Pakistan. Patients were
divided into three cohorts, (i) 2006-08, (ii) 2008-09 and
(iii) 2009-10; first as initial cohort and later two as valida-
tion cohort to find appropriate relationship between viral
and host serum markers. Blood samples (10 mL) were col-
lected from each patient and tested for anti-HCV antibody
by ELISA (Abbot Laboratories) at Jinnah Hospital Lahore.
Patients with positive serology and/or positive test for
HCV alone and no evidence of liver failure were included
in this study. Patients who were not keen to give informed
consent, not able to make follow-up visits and not willing
to undergo genetic testing and not allow samples to be
stored for future research were excluded from the study.
Accordingly, thus, a total of 6048 HCV-RNA positive
patients were identified. The routine liver function tests
(LFTs), Hb level and direct bilirubin were estimated for
each patient in the hospital laboratory by using commer-
cially available Hitachi-7600 series analyzer. Questionnaire
(including their personal, lab tests and demographical
information) was prepared for patients who came for HCV
initial screening and further genotyping and viral load
quantification. Informed consents were (containing per-
mission to do liver biopsy, procedure of liver biopsy and
the possible risks associated with liver biopsy were men-
tioned) obtained from those patients who were willing to
do so. Only patients aged 18 or above were considered for
liver biopsy samples. Patients less than 18 years were only
included in genotyping and biochemical data analysis etc.
Regarding consent obtained from under 18 years children,
parents signed and filled the questionnaire. The study was
approved by the institutional ethical committee.
HCV viral assays
HCV viral detection and genotyping was carried out at
the Department of Pathology, Jinnah Hospital, Lahore,
Mayo Hospital, Lahore and Liver Center, Faisalabad,
Pakistan. QIAamp viral RNA extraction kit (Qiagen,
USA) was used to extract HCV RNA from serum (150
μl) according to the manufacturer’s protocol. The
extracted RNA was reverse transcribed to cDNA using
Moloney murine leukemia virus (MmLV) followed by
PCR at 5`UTR non-coding region of HCV genome
using primers described by Chan et al. 1992 [17]. After
qualitative PCR analysis, Qiagen HCV RG RT-PCR
assay was used for the quantification of viral RNA.
Briefly 10ul of the extracted RNA was mixed with PCR
mix and fluorescent probes and quantified on Rotor-
gene Real-Time PCR machine (USA), amplification was
detected after each replicating cycle as described by
manufacturer protocol. The lower limit of detection for
this assay is 1000 IU/ml. Invader HCV genotyping assay
(Third wave technology, USA) was used for genotyping
analysis. HCV RNA (100ng) was reverse transcribed to
cDNA using 200U of MmLV (Invitrogen, USA). For
genotyping assay, 2 μl of the cDNA was amplified and
assay for 12 different HCV types was performed.
Histological evaluation of biopsy samples
METAVIR scoring system was used for the histological
evaluation of 157 paraffin-embedded liver specimens at
Pathology Department Jinnah Hospital, Lahore [18].
Liver biopsies were evaluated by two independent
pathologists without former information to patient’s his-
tory. Liver histological staging was based on five degrees
of fibrosis: as F0 (no fibrosis), F1 (mild fibrosis without
septa) F2 (moderate fibrosis with few septa), F3 (severe
fibrosis with numerous septa without cirrhosis) and F4
(cirrhosis). These stages were further grouped as F0-F1
(no/minimal fibrosis), F2-F3 (advanced fibrosis) and F4
(cirrhosis).
Viral factors association with host biochemical factors
Viral factors like genotype and viral load were correlated
with host biochemical conditions like ALT, AST, ALP,
bilirubin and Hb level. We also checked this correlation
in different fibrosis stages.
Statistical analysis
Statistical analysis was performed using the statistical
package for social studies (SPSS) version 16 for win-
dows. Student t-test and Chi-square tests were applied
to evaluate differences in proportions. P value <0.05 was
considered significant. Univariate analysis includes the
variables age, sex, Hb level, bilirubin, ALT, AST, ALP
and viral load. Age, sex and genotypes were taken as
independent categorical factors. Multiple regression ana-
lysis was used to evaluate independent associations
between HCV genotypes and biochemical values. The
relationship between serum markers and viral load was
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analyzed by Spearman’s correlation for non-parametric
data.
Results
Prevalence of HCV infection
Patients were divided in three cohorts. Overall, out of
6048 patients, 3066 (50.7%) were male while 2982
(49.3%) were female. The first cohort was observational
cohort while, the successive years data was validation
cohort. The mean age of patients was 37.40 ± 10.9 years
(range 6-75), while 3815 (63.1%) patients were ≤ 40 year
of age. Table 1 briefly outlined patients’ data for each
cohort.
Genotype distribution among patients
Based on weighted analysis of patients infected with
HCV in all cohorts, the most frequently detected geno-
type was 3 (70.9%), with predominant subtype 3a
(64.5%) and 3b (6.4%). Genotype 1 (13.3%) was con-
sisted of the subtype 1a (12.1%) and 1b (1.2%), while
genotype 4 (7.4%) comprised the subtype a (6.7%) and
b (0.6%). Patients with genotype 5a (0.5%) and 6a
(0.4%) were also present. Patients with mix genotypes
(3.3%) and undefined genotype (2.4%) were also identi-
fied. The frequency distribution of different genotypes
is given in Table 1, while Figure 1 illustrates the distri-
bution of genotypes subtypes and mix genotypes in full
cohort.
Association of age, gender, viral load and host serum
markers with genotypes
Overall prevalence of genotypes within gender and age
groups is given in Table 2. Distribution of genotypes
within gender was statistically non-significant (P =
0.290), however, incidence of genotypes among age
groups (≤ 40 and ≥40) was statistically different (P =
0.000). Overall, median value of viral load and host
serum markers in each genotype is also given in table 2.
Univariate analysis (Table 3) revealed that in three
cohorts’ serum bilirubin, ALP, ALT and AAR (AST/
ALT ratio) were significantly different among genotypes.
Figure 2 shows overall median of these four significant
variables in different genotypes subtypes and mix geno-
types. We observed significant elevated bilirubin, ALP














Male 1515 (47.9%) 718 (52.6%) 833 (54.7%) 3066 (50.7%)
Female 1645 (52.1%) 646 (47.4%) 691 (45.3%) 2982 (49.3%)
Age
Mean 37.08 ± 10.33 37.15 ± 11.65 38.29 ± 11.361 37.40 ± 10.91
Range 6-75 12-71 10-75 6-75
Age Group
<40 2119 (67.1%) 832 (61.0%) 864 (56.7%) 3815 (63.1%)
>40 1041 (32.9%) 532 (39.0%) 660 (43.3%) 2233 (36.9%)
Biochemical Markers (All values in median (Range)
Viral titer (IU/mL) 1.0 × 107 (1340-8.5 × 108) 3.20 × 105 (10000-4.0 × 108) 1.8 × 107 (10000-4.0 × 108) 2.0 × 106 (1340-8.5 × 108)
Hb level(mg/dl) 13.1 (9.8-16.7) 14.0 (13.1-16.9) 11.4 (8.8-15.6) 13.1 (8.8-16.9)
Bilirubin (mg/dl) 0.80 (0.1-1.3) 0.80 (0.3-1.2) 0.80 (0.1-1.9) 0.80 (0.1-1.9)
ALP (IU/mL) 185.0 (85-421) 165.0 (30-396) 165.5 (30-392) 176.0 (24-421)
ALT (IU/mL) 58.0 (14-238) 57.0 (13-311) 59.0 (11-308) 58.0 (11-311)
AST (IU/mL) 56.0 (13-230) 55.0 (16-218) 57.0 (19-236) 56 (13-236)
AAR 0.96 ± (0.155.75) 0.96 (0.07-7.50) 0.98 (0.06-9.09) 0.96 (0.06-9.09)
Genotypes
1 365 (11.6%) 206 (15.1%) 231 (15.2%) 802 (13.3%)
2 31 (1.0%) 27 (2.0%) 55 (3.6%) 113 (1.9%)
3 2359 (74.7%) 934 (68.5%) 994 (65.2%) 4287 (70.9%)
4 224 (7.1%) 89 (6.5%) 133 (8.7%) 446 (7.4%)
5 28 (0.9%) 0 3 (0.2%) 31 (0.5%)
6 19 (0.6%) 4 (0.3%) 3 (0.2%) 26 (0.4%)
Mix 96 (3.0%) 46 (3.4%) 55 (3.6%) 197 (3.3%)
Undefined 38 (1.2%) 58 (4.3%) 50 (3.3%) 146 (2.4%)
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and AST levels, and low AAR value in patients infected
with genotype 4 when compared to other genotypes.
Correlation of serum markers and viral load
Correlation of serum markers with viral load in HCV
infected patients is illustrated in Figure 3, it shows that
viral load has negative correlation with bilirubin (r =
-0.112, P = 0.000) and ALP (r = -0.098, P = 0.000),
while a linear significant correlation of viral load and
ALT was found (r = 0.027, P = 0.046). We observed
non significant correlation of serum viral load with Hb
level, AST and AAR.
Association of genotypes and viral load with serum
markers among fibrosis stages
The clinical outcomes of the 157 HCV infected patients
who underwent biopsy are briefly explained in Table 4.
Figure 1 Distribution of genotypes subtypes and mix genotypes in patients. Genotype 3a was most frequent followed by 1a, 4a and 3b.
Table 2 Distribution of genotypes according to gender
and age of patients
Variables Genotypes
1 2 3 4 5 6 Mix Undefined
Gender
Male 389 59 2178 226 18 14 94 88
Female 413 54 2109 220 13 12 103 58
Age groups
≤ 40 549 74 2630 304 29 23 124 82
≥ 40 253 39 1657 142 2 3 73 64
Table 3 Univariate analysis of biochemical markers in
each cohort with respect to genotypes
Dependent
Variable









Hb Level (mg/dl) 40.762 5.823 1.590 0.133
Bilirubin (mg/dl) 2.736 0.391 11.654 0.000
ALP (IU/mL) 2226420.139 318060.020 93.011 0.000
ALT (IU/mL) 294609.549 42087.078 36.947 0.000
AST (IU/mL) 7017.662 1002.523 .844 0.551
AAR 47.574 6.796 12.561 0.000
Viral load (IU/mL) 3.792 × 108 5.418 × 107 40.886 0.000
Second Cohort
Hb Level (mg/dl) 26.434 4.406 3.399 0.002
Bilirubin (mg/dl) 2.841 0.474 14.248 0.000
ALP (IU/mL) 945658.653 157609.776 35.570 0.000
ALT (IU/mL) 382870.009 63811.668 42.701 0.000
AST (IU/mL) 13693.220 2282.203 2.028 0.059
AAR 28.938 4.823 5.506 0.000
Viral load (IU/mL) 3.020 × 106 5.034 × 105 2.911 0.008
Third Cohort
Hb Level (mg/dl) 4.474 0.639 0.577 0.775
Bilirubin (mg/dl) 4.028 0.575 16.770 0.000
ALP (IU/mL) 1210130.199 172875.743 36.993 0.000
ALT (IU/mL) 772255.261 110322.180 78.063 0.000
AST (IU/mL) 23722.212 3388.887 2.348 0.022
AAR 69.294 9.899 11.921 0.000
Viral load (IU/mL) 3.324 × 106 4.749 × 105 1.927 0.062
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The determination of liver fibrosis showed stage F0-F1
and F2-F3 in 63 patients each, while in F4 or advanced
fibrosis leading to cirrhosis there were 21 patients. Gen-
otype 3a and 1a were identified in 135 and 22 patients,
respectively.
Fibrosis stages were independent of genotype of the
patients. Univariate analysis showed that serum viral
load, bilirubin, ALP and AST levels were significantly
different among fibrosis stages. Meanwhile, a strong
significant negative correlation of viral load with biliru-
bin (r = -0.221, P = 0.005) and ALP (r = -0.236, P =
0.003) was observed as shown in Figure 4.
Discussion
The basic aim of this study was to find out the associa-
tion of genotypes and viral load with host age, gender
and biochemical outcome and, their association with
liver fibrosis progression. Our patient’s data showed no
Figure 2 Box plot of bilirubin, ALP, ALT and AAR for genotypes. The horizontal line inside each box represents the median, while the top
and bottom of boxes represent the 25th and 75th percentiles, respectively. Vertical lines from the ends of the box encompass the extreme data
points.
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significant differences in genotype distribution in rela-
tion to gender. Various genotypes, particularly 1, 3 and
4 were equally distributed in gender. However, we
observed more HCV dominance in patients with age ≤
40 years. May be this was due to early assessment of
disease. Prevalence of genotypes in our study was: geno-
type 3 (n = 4287, 70.9%), followed by genotype 1 (n =
802, 13.3%) and genotype 4 (n = 446, 7.4%). Subtypes
3a, 1a and 4a were predominant, whereas mix subtype
4a/5a was also found in some patients (n = 26, 0.4%).
Among patients, 2.4% (n = 146) showed untypable geno-
type. The high prevalence of genotype 3 followed by 1a
is according to the previous studies conducted in Paki-
stan [1,8,19]. Idress et al. 2008 reported increased preva-
lence of HCV infection due to genotype 4 and 1 without
increase in frequency of genotype 3 in various areas of
Pakistan mainly Khyber Pakhtoon Khawa (1a, 6.56% and
4, 2.30%) and Balochistan (1a, 25.80% and 4, 4.03%).
Our results indicated a 4-5 fold increased prevalence of
genotype 4 in Pakistan (1.49% to 7.4%). Moreover, geno-
type 4 is reported to be associated with liver cirrhosis
[20]; there may be risk of increased liver cirrhosis in
Pakistan as the percentage of genotype 4 is increasing.
Evaluating the correlation between different clinical
markers with genotypes, we observed that four clinical
markers AST, ALP, bilirubin level and AAR were
significant in all three cohorts’ one initial and two vali-
dation cohort. This may lead to conclude that these
four biochemical markers may be used to differentiate
genotypes. However, all genotypes except genotype 4
showed approximately same levels of serum markers
bilirubin, ALP, ALT and AAR in patients as shown in
Figure 2. We observed significantly high bilirubin, ALP
and AST levels in patients with genotype 4 while, the
AAR ratio for genotype 4 was considerably lower than
other genotypes.
Concerning correlation of viral load with biochemical
markers, we found a positive but very weak correlation
of ALT with viral load, while a strong negative correla-
tion with bilirubin and serum ALP levels. Weak correla-
tion of serum viremia levels with ALT in our study was
in agreement with outcome of Azzari et al. 2000 and
Murakami et al. 2004 that the viral load was indepen-
dent of ALT activity in HCV [13,21]. Zechini et al. 2004
found a relation between HCV viral load and AST.
However, we could not observe any correlation between
viral load and AST that may be due to poor immune
response resulting in uneven AST level and viral load
and lead to liver damage [22].
High bilirubin level is usually associated with liver
metastases and liver tumor involvement leading to hepa-
tocellular carcinoma and liver cirrhosis by active or non-
Figure 3 Spearman correlation of biochemical markers with viral load in overall patients. Correlation P < 0.05 was considered significant.
Serum level of bilirubin and ALP were negatively, while ALT was positively associated with viral load in patients infected with HCV.
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active HCV or HBV [23]. Bilirubin has been reported as
marker of liver injury and to determine the proper dose
of interferon in patients with different genotypes [14].
As different genotypes lead to diverse severity of liver
disease so the treatment plan of chronic HCV infection
with interferon varies with the genotype being treated
[24].
Elevated aminotransferases levels act as indicators of
liver cell injury [21,25] and are usually predominant in
liver cirrhosis with increased ALT levels [26]. We
observed mild increase in AST and elevated ALT level
in genotype 4 as compared to other genotypes. These
results could lead to the confirmation of association of
genotype 4 with increased risk of cirrhosis [20].
In our study, patients with genotype 4 reflected high
ALP levels as compared to others. Recent studies revealed
that the higher levels of ALP are usually associated with
liver metastasis, extra-hepatic bile obstruction, primary
biliary cirrhosis, intrahepatic cholestasis, infiltrative liver
disease, hepatitis, cirrhosis, primary sclerosing cholangitis,
hepatic lymphoma, liver abscess, sarcoidosis and conges-
tive cardiac failure. A change in ALP levels greater than
120 U/L can be indicative of advanced disease progression
[27-29].
Although high AAR value indicates more chances of cir-
rhosis, we found low AAR levels for genotype 4 as com-
pared to others leading less chances of cirrhosis; but
according to Reedy et al. (1998), this test cannot predict
significant cirrhosis in patients with chronic hepatitis C
[30]. We also observed slightly low Hb levels in HCV
patients irrespective of genotype. As HCV is associated
with many extra hepatic complications, decline of Hb level
with the increase of viral load in HCV may lead to autoim-
mune haemolytic anemia (AIHA) that can contribute to
enhance the liver cirrhosis especially in patients with geno-
types 1-4 as the patients with HCV related AIHA have
higher prevalence of cirrhosis [31]. Higher ALP and biliru-
bin levels and mild increase in AST levels in patients with
genotype 4 may also lead to cholestatic hepatitis that is a
severe form of HCV recurrence after treatment and organ
transplantation like liver, kidney and heart [24,32].
We got consistent correlation of ALP, AST, bilirubin,
with viral load and genotypes in all three cohorts that is
initial cohort and two validation cohorts (Figure 3). We
further evaluated the relation of these serum markers
with fibrosis stages. As host factors reflect the disease
progression, we found that serum bilirubin, ALP and
AST gradually increased as fibrosis progressed (Table 4).
Figure 4 Spearman correlation of biochemical markers with viral load in patients with histopathological stages. Correlation P < 0.05 was
considered as significant. Bilirubin and ALP levels were negatively associated with viral load and were significantly raised in advanced stages of
fibrosis.
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Fibrosis progression was found to be independent of
genotypes, while we found a significant correlation
between serum HCV RNA levels and fibrosis stages as
shown in Figure 4 (Table 4). As genotype 4 showed dif-
ferent results compare to other genotypes with serum
markers we were unable to confirm these results in
biopsy samples as we only get biopsy samples of geno-
type 3 and 1. Our previous pilot study also showed
same trend [33]. Kato et al. monitored significantly
higher HCV RNA level in patients with chronic active
hepatitis and cirrhosis compared to chronic persistent
hepatitis [31]. Serum HCV RNA level has linear rela-
tionship with amount of virus in the liver that is in
accordance to De Moliner et al. 1998 results [34]. In
our study, we observed relatively high viral load in initial
fibrosis stages (F0-F1) compared to advance fibrosis
stages (F2-F3). An interesting finding was significantly
lower viral RNA levels and high bilirubin, AST and ALP
in cirrhosis (F4). The increased AST level had been
attributed to mitochondrial injury associated with HCV
infection and progression of liver fibrosis [35]. In cirrho-
tic stage (F4) decline in serum HCV RNA levels could
be due to reduce number of hepatocytes and advance
fibrosis which results in shrinking of liver mass [33]. We
also observed a steady increase in serum ALP and biliru-
bin levels in advanced stage F3 as compared to initial
fibrosis (F0-F2) stages that usually observed in signifi-
cant liver disease or in hepatocellular carcinoma
[23,27,28,35,36].
In conclusion, host serum biochemical factors were
not found to be dependent on genotype except for gen-
otype 4, where we observed high level of bilirubin, ALP,
ALT and lower AAR. In general, viral load showed sig-
nificant correlation with bilirubin, ALP and ALT. To
confirm these results and finding; viral-host association
with disease progression was evaluated in liver biopsy
samples. We observed that lower viral load and elevated
bilirubin; ALP and AST levels are associated with more
advanced fibrosis leading to cirrhosis. It is conceivable
that serum viral load, AST, ALP and bilirubin levels are
suitable factors that can determine liver damage.
Although, genotype 4 showed significant variable
response to the serum markers, we recommend geno-
typing assay to find possible association with disease
severity and guide about treatment duration and out-
comes. Future studies are required to see the relation of
the serum markers with genotype 4a infected biopsy
samples to find any relation with disease progression.
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